BioSpace News Archive

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, announced the completion of its business combination with First Light Acquisition Group, a special purpose acquisition company.

Singleron has announced the launch of its AccuraCode® TCR library construction kit for high-throughput T-cell receptor profiling.

Immuron Limited is pleased to announce record monthly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.

Dignify Therapeutics announced that it has entered into a licensing agreement with Aayam Therapeutics to develop compound ATX-003 and related proprietary molecules for on-demand defecation.

NanoString Technologies, a leading provider of life science tools for discovery and translational research, announced the launch of the latest assay for the GeoMx® Digital Spatial Profiler.

Alzheon, Inc. announced statistically significant and clinically relevant reduction in plasma biomarkers of neurodegeneration, preservation of brain volume, and positive cognitive effects in Early AD patients who are carriers of apolipoprotein ε4 allele following 24 months of treatment with investigational agent ALZ-801 in the Phase 2 biomarker trial.

Subtle Medical was awarded a federal SBIR grant from the National Institutes of Health to expand their artificial intelligence -powered software solution, SubtleSYNTH™, which uses deep learning to synthesize Magnetic Resonance Imaging contrasts from already-acquired contrasts.

Moderna, Inc. announced business and clinical updates across its franchises and introduced several new development programs at the Company’s annual R&D Day.

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5 ® Advanced Wound System.

Culture Biosciences , a leading provider of innovative, future-forward bioprocessing solutions, is pleased to announce the appointment of Darcy Birse as the company’s new Chief Commercial Officer (CCO).